Congress Park Capital LLC Madrigal Pharmaceuticals, Inc. Transaction History

Congress Park Capital LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 15, 2024	BUY	$171.37 - $283.23 $205,644 - $339,876	1,200 New	1,200 $320,000
Q4 2022 Jan 27, 2023	SELL	$58.39 - $296.54 $143,055 - $726,523	-2,450 Reduced 75.38%	800 $232,000
Q2 2022 Jul 22, 2022	SELL	$58.04 - $100.2 $580 - $1,002	-10 Reduced 0.31%	3,250 $233,000
Q1 2022 May 02, 2022	BUY	$55.89 - $101.89 $18,723 - $34,133	335 Added 11.45%	3,260 $320,000
Q4 2021 Feb 09, 2022	BUY	$72.34 - $95.09 $211,594 - $278,138	2,925 New	2,925 $248,000

296

21.9M

819K

644K

Ticker MDGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,103,400
Market Cap $5.52B
Description
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...

Get notified when there are updates to the investment portfolio of Congress Park Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Congress Park Capital LLC with notifications on news.